In this podcast episode, our experts discuss the changing face of medicine and what it means for patients. 

Many companies are investing in large molecule technologies because it allows for more targeted therapies. For example, the traditional therapy for cancer is chemotherapy, but it’s nonspecific, So it could wreak havoc on cells that you want to leave alone – the healthy cells.

With advances in antibody research, cancer treatment is evolving.  How do scientists know when immunogenicity might be desirable? 

Listen to the podcast here